Filippo Pietrantonio

16.0k total citations · 4 hit papers
298 papers, 5.0k citations indexed

About

Filippo Pietrantonio is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Pathology and Forensic Medicine. According to data from OpenAlex, Filippo Pietrantonio has authored 298 papers receiving a total of 5.0k indexed citations (citations by other indexed papers that have themselves been cited), including 224 papers in Oncology, 124 papers in Pulmonary and Respiratory Medicine and 81 papers in Pathology and Forensic Medicine. Recurrent topics in Filippo Pietrantonio's work include Colorectal Cancer Treatments and Studies (183 papers), Gastric Cancer Management and Outcomes (78 papers) and Genetic factors in colorectal cancer (75 papers). Filippo Pietrantonio is often cited by papers focused on Colorectal Cancer Treatments and Studies (183 papers), Gastric Cancer Management and Outcomes (78 papers) and Genetic factors in colorectal cancer (75 papers). Filippo Pietrantonio collaborates with scholars based in Italy, United States and Spain. Filippo Pietrantonio's co-authors include Filippo de Braud, Maria Di Bartolomeo, Claudia Maggi, Fausto Petrelli, Chiara Cremolini, Roberto Iacovelli, Sara Lonardi, Ilaria Bossi, Silvia Giordano and Simona Corso and has published in prestigious journals such as New England Journal of Medicine, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Filippo Pietrantonio

279 papers receiving 4.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: A meta-analysis

2015 350 citations Filippo Pietrantonio, Maria Di Bartolomeo et al. European Journal of Cancer profile →
Sotorasib plus Panitumumab in Refractory Colorectal Cancer with Mutated KRAS G12C

2023 163 citations Marwan Fakih, Lisa Salvatore et al. profile →
NALIRIFOX, FOLFIRINOX, and Gemcitabine With Nab-Paclitaxel as First-Line Chemotherapy for Metastatic Pancreatic Cancer

2024 47 citations Federico Nichetti, Carlo Sposito et al. profile →
Epidemiology, pathogenesis, biology and evolving management of MSI-H/dMMR cancers

2025 13 citations Margherita Ambrosini, Julien Taı̈eb et al. profile →

Peers

Countries citing papers authored by Filippo Pietrantonio

Since Specialization

Citations

This map shows the geographic impact of Filippo Pietrantonio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filippo Pietrantonio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filippo Pietrantonio more than expected).

Fields of papers citing papers by Filippo Pietrantonio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Filippo Pietrantonio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filippo Pietrantonio. The network helps show where Filippo Pietrantonio may publish in the future.

Co-authorship network of co-authors of Filippo Pietrantonio

This figure shows the co-authorship network connecting the top 25 collaborators of Filippo Pietrantonio. A scholar is included among the top collaborators of Filippo Pietrantonio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filippo Pietrantonio. Filippo Pietrantonio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Overall Survival Analysis of the Phase III CodeBreaK 300 Study of Sotorasib Plus Panitumumab Versus Investigator's Choice in Chemorefractory KRAS G12C Colorectal Cancer 2025 ·Journal of Clinical Oncology ·Filippo Pietrantonio, Lisa Salvatore, Taito Esaki, Dominik Paul Modest, D. Páez López-Bravo, Julien Taı̈eb, Michalis V. Karamouzis, Erika Ruíz‐García, Tae Won Kim, Yasutoshi Kuboki, Fausto Meriggi, David Cunningham, Kun‐Huei Yeh, Emily Chan, Joseph Chao, Qui Tran, Chiara Cremolini, Marwan Fakih	7
2	The relative dose intensity of first-line FOLFOXIRI and FOLFOX/FOLFIRI both in combination with bevacizumab affects prognosis of metastatic colorectal cancer patients: A pooled analysis of TRIBE and TRIBE2 studies 2025 ·European Journal of Cancer ·Roberto Moretto, Daniele Rossini, (unknown), Carlotta Antoniotti, Rossana Intini, Veronica Conca, (unknown), (unknown), Lisa Salvatore, Marco Maria Germani, Francesca Bergamo, Alessandro Passardi, (unknown), Emiliano Tamburini, (unknown), (unknown), Gianluca Masi, Filippo Pietrantonio, Sara Lonardi, Chiara Cremolini	0
3	Liquid Biopsy in Peritoneal Carcinomatosis from Colorectal Cancer: Current Evidence and Future Perspectives 2025 ·Cancers ·Valentino Martelli, Joana Vidal, Sílvia Salvans, Concepción Fernández, Jordi Badia-Ramentol, Jenniffer Linares, Marta Jiménez‐Toscano, Annarita Sibilio, (unknown), (unknown), Beatríz Bellosillo, Alexandre Calon, Filippo Pietrantonio, Mar Iglesias, Marta Pascual, Clara Montagut	1
4	Gender Difference in sidE eFfects of ImmuNotherapy: a possible clue to optimize cancEr tReatment (G-DEFINER): study protocol of an observational prospective multicenter study 2024 ·Acta Oncologica ·Rosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, Salvatore Alfieri, Maria Moksnes Bjaanæs, Filippo Pietrantonio, Loris De Cecco, Arsela Prelaj, Claudia Proto, (unknown), (unknown), (unknown), (unknown), Laura Mazzeo, Patrizia Giannatempo, Elena Verzoni, John Crown, Åslaug Helland, Alex J. Eustace	3
5	Detecting BRAF mutations in colorectal cancer in clinical practice: An Italian experts' position paper 2024 ·Critical Reviews in Oncology/Hematology ·(unknown), Valentina Angerilli, Rossana Intini, Francesca Bergamo, Chiara Cremolini, Federica Grillo, Elena Guerini‐Rocco, Tiziana Pia Latiano, Erika Martinelli, Nicola Normanno, Fabio Pagni, Paola Parente, Alessandro Pastorino, Filippo Pietrantonio, Lisa Salvatore, Sara Lonardi, Matteo Fassan	3
6	Non-invasive CT radiomic biomarkers predict microsatellite stability status in colorectal cancer: a multicenter validation study 2024 ·European Radiology Experimental ·Zuhir Bodalal, Eun Kyoung Hong, Stefano Trebeschi, Ieva Kurilova, (unknown), (unknown), (unknown), Giovanni Randon, Pétur Snæbjörnsson, Filippo Pietrantonio, Jeong Min Lee, Geerard L. Beets, Regina G. H. Beets‐Tan	8
7	Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: The ARMANI phase III trial. 2024 ·Journal of Clinical Oncology ·Filippo Pietrantonio, Giovanni Randon, Sara Lonardi, Silvio Ken Garattini, Stefano Tamberi, Elisa Giommoni, Samantha Di Donato, Lorenzo Fornaro, Oronzo Brunetti, Ferdinando De Vita, Giovanni Luca Frassineti, Claudio Chini, Andrea Spallanzani, (unknown), Antonia Strippoli, Tiziana Pia Latiano, Giovanni Gerardo Cardellino, Federica Palermo, Rosalba Miceli, Maria Di Bartolomeo	3
8	Updated results and subgroup analysis by presence of liver metastases of a phase I/II study of the EP4 antagonist vorbipiprant with the anti-PD-1 balstilimab in mismatch-repair-proficient and microsatellite stable (pMMR/MSS) chemorefractory metastatic colorectal cancer (mCRC). 2024 ·Journal of Clinical Oncology ·Filippo Pietrantonio, Federica Morano, (unknown), (unknown), Claudia Chiodoni, (unknown), (unknown), (unknown), Elena Benincasa, Giampaolo Giacovelli, (unknown), (unknown), Lucio C. Rovati	1
9	Negative hyperselection and mechanisms of acquired resistance to first-line chemotherapy plus anti-EGFR in patients (pts) with pMMR RAS/BRAF wild-type (wt) metastatic colorectal cancer (mCRC): A translational analysis of the TRIPLETE trial. 2024 ·Journal of Clinical Oncology ·Veronica Conca, (unknown), Paola Vignali, Daniele Rossini, Marco Maria Germani, Francesca Bergamo, Filippo Pietrantonio, Beatrice Borelli, Federica Marmorino, Mirella Giordano, Giovanni Randon, (unknown), (unknown), (unknown), Angela Buonadonna, Alberto Zaniboni, Lorenzo Antonuzzo, Gianluca Masi, Clara Ugolini, Chiara Cremolini	0
10	Use of circulating tumor DNA (ctDNA) to affect the adjuvant or post-adjuvant treatment of patients with stage III and high-risk stage II resected colon cancer: The ERASE-CRC project by GONO. 2024 ·Journal of Clinical Oncology ·Veronica Conca, (unknown), Roberto Moretto, Sara Lonardi, Carlotta Antoniotti, Marco Maria Germani, Filippo Pietrantonio, Alessandro Bittoni, (unknown), Lisa Salvatore, Alessandra Boccaccino, Monica Ronzoni, (unknown), (unknown), Samanta Cupini, Tiziana Pia Latiano, Giuseppina Arcangeli, Gabriele Masi, Matteo Fassan, Chiara Cremolini	1
11	Treatment of patients with BRAF-mutated metastatic colorectal cancer after progression to encorafenib and cetuximab: data from a real-world nationwide dataset 2024 ·ESMO Open ·Marco Maria Germani, (unknown), (unknown), Rossana Intini, (unknown), Maria Bensi, Alessandra Boccaccino, Alessandro Minelli, (unknown), (unknown), Alessandro Passardi, (unknown), Riccardo Giampieri, Mara Persano, Elisabetta Fenocchio, Alberto Puccini, Sara Lonardi, Filippo Pietrantonio, Lisa Salvatore, Chiara Cremolini	4
12	Immune checkpoint inhibitors in advanced gastroesophageal adenocarcinoma: a series of patient-level meta-analyses in different programmed death-ligand 1 subgroups 2024 ·ESMO Open ·Alberto Giovanni Leone, Antonello Mai, Khi Yung Fong, Dominic Wei Ting Yap, Ken Kato, (unknown), Markus Moehler, Jeremy Tey, Raghav Sundar, Joseph J. Zhao, Filippo Pietrantonio	6
13	Liver Transplantation for Hepatic Metastases from Colorectal Cancer: Current Knowledge and Open Issues 2023 ·Cancers ·Marianna Maspero, Carlo Sposito, (unknown), Davide Citterio, Filippo Pietrantonio, Sherrie Bhoori, Filiberto Belli, Vincenzo Mazzaferro	16
14	Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 2023 ·Cancers ·Davide Ciardiello, Stefania Napolitano, Vincenzo Famiglietti, Lucia Esposito, Vincenzo De Falco, (unknown), Antonio Avallone, Evaristo Maiello, Filippo Pietrantonio, Chiara Cremolini, Maria Giulia Zampino, Nicola Fazio, Teresa Troiani, Erika Martinelli, Fortunato Ciardiello, Giulia Martini	6
15	LBA28 The PEGASUS trial: Post-surgical liquid biopsy-guided treatment of stage III and high-risk stage II colon cancer patients 2023 ·Annals of Oncology ·Sara Lonardi, Filippo Pietrantonio, (unknown), (unknown), (unknown), Maria Giulia Zampino, (unknown), (unknown), Mario Mandalà, Stefano Tamberi, (unknown), Susana Muñoz, Luca Lazzari, Paolo Luraghi, Valter Torri, Andrés Cervantes, Alberto Bardelli, Josep Tabernero, Salvatore Siena, Silvia Marsoni	32
16	Association of immune-related adverse events with the outcomes of immune checkpoint inhibitors in patients with dMMR/MSI-H metastatic colorectal cancer 2023 ·Journal for ImmunoTherapy of Cancer ·(unknown), Francesco Barretta, Francesca Corti, Sara Lonardi, Monica Niger, María Elena Elez, Marwan Fakih, Priya Jayachandran, (unknown), Massimiliano Salati, Elisabetta Fenocchio, Lisa Salvatore, Chiara Cremolini, Javier Ros, Margherita Ambrosini, (unknown), Rossana Intini, Michael J. Overman, Rosalba Miceli, Filippo Pietrantonio	13
17	Comparative Genomic Analysis and Clinical Outcomes of BRAF -mutated Advanced Biliary Tract Cancers 2023 ·Clinical Cancer Research ·(unknown), Federico Nichetti, (unknown), Sara Lonardi, Filippo Pietrantonio, Lisa Salvatore, Caterina Vivaldi, Lorenza Rimassa, Filippo de Braud, Mario Domenico Rizzato, Dean C. Pavlick, (unknown), (unknown), Radwa Sharaf, Ethan Sokol, Jordi Rodón, Jeffrey S. Ross, Milind Javle, Monica Niger	8
18	Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study 2022 ·The Oncologist ·Giovanni Fucà, Alessandra Raimondi, Michele Prisciandaro, Sara Lonardi, Chiara Cremolini, Margherita Ratti, Matteo Clavarezza, Roberto Murialdo, Andrea Sartore‐Bianchi, Valeria Smiroldo, Rosa Berenato, Patrizia Racca, Francesca Bergamo, Salvatore Corallo, Maria Di Bartolomeo, Filippo de Braud, Federica Morano, Filippo Pietrantonio	5
19	Bright-fieldin situhybridization detects gene alterations and viral infections useful for personalized management of cancer patients 2018 ·Expert Review of Molecular Diagnostics ·Chiara Costanza Volpi, Ambra V. Gualeni, Filippo Pietrantonio, Emanuela Vaccher, Antonino Carbone, Annunziata Gloghini	6
20	MET-Driven Resistance to Dual EGFR and BRAF Blockade May Be Overcome by Switching from EGFR to MET Inhibition in BRAF -Mutated Colorectal Cancer 2016 ·Cancer Discovery ·Filippo Pietrantonio, Daniele Oddo, Annunziata Gloghini, Emanuele Valtorta, Rosa Berenato, Ludovic Barault, Marta Caporale, Adele Busico, Federica Morano, Ambra V. Gualeni, Alessandra Alessi, Giulia Siravegna, Federica Perrone, Maria Di Bartolomeo, Alberto Bardelli, Filippo de Braud, Federica Di Nicolantonio	78

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact